The value of initial cavitation to predict re-treatment with pulmonary tuberculosis

European Journal of Medical Research

Volumn 21, Issue 1, 2016, Pages

  Huang, Qiusheng ^b   Yin, Yongmei ^a   Kuai, Shougang ^a   Yan, Yan ^a   Liu, Jun ^a   Zhang, YingYing ^a   Shan, Zhongbao ^a   Gu, Lan ^a   Pei, Hao ^a   Wang, Jun ^a  

^a JIANGNAN UNIVERSITY   (China)

^b Second Peoples' Hospital   (China)

Author keywords

Cavitation; Pulmonary tuberculosis; Re treatment

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETREATMENT; SMOKING; THORAX RADIOGRAPHY; COMPLICATION; DRUG EFFECTS; LUNG INFARCTION; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PATHOPHYSIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; PULMONARY INFARCTION; RETREATMENT; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84969567640     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/s40001-016-0214-0     Document Type: Article

References (19)

1. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
2. Hill AN, Becerra J, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect. 2012;140(10):1862-72.
3. Surveillance report: tuberculosis surveillance and monitoring in Europe 2013. Geneva: World Health Organization; 2013.
4. Public Health England. Tuberculosis in the UK 2013 report. London: Public Health England; 2013.
5. Crofts JP, Andrews NJ, Barker RD, Delpech V, Abubakar I. Risk factors for recurrent tuberculosis in England and Wales, 1998-2005. Thorax. 2010;65(4):310-4.
6. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization; 2010.
7. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159(3):733-40.
8. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057-64.
9. Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, Vashakidze S. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012;54(6):e51-4.
10. Chatterjee A, D'Souza D, Vira T, Bamne A, Ambe GT, Nicol MP, Wilkinson RJ, Mistry N. Strains of mycobacterium tuberculosis from western Maharashtra, India, exhibit a high degree of diversity and strain-specific associations with drug resistance, cavitary disease, and treatment failure. J Clin Microbiol. 2010;48(10):3593-9.
11. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528-34.
12. Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M. Predicting tuberculosis treatment outcome in a low-incidence area. Int J Tuberc Lung Dis. 2008;12(12):1441-8.
13. East African/British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am Rev Respir Dis. 1981;123(2):165-70.
14. Zierski M, Bek E, Long MW, Jr Snider D E. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1981;124(3):249-51.
15. Ong CW, Elkington PT, Friedland JS. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med. 2014;190(1):9-18.
16. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003;71(12):7099-108.
17. Barry S, Breen R, Lipman M, Johnson M, Janossy G. Impaired antigen-specific CD4 + T lymphocyte responses in cavitary tuberculosis. Tuberculosis. 2009;89(1):48-53.
18. Bam TS, Gunneberg C, Chamroonsawasdi K, Bam DS, Aalberg O. Factors affecting patient adherence to DOTS in urban Kathmandu. Nepal. Int J Tuberc Lung Dis. 2006;10(3):270-6.
19. Chang KC, Leung CC, Tam CM. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis. 2004;8(12):1492-8.